MedTrace Logo

A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease

NCT05426382 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-04-26

No results posted yet for this study

Summary

Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD). The SK-241 is delivered through a mobile application and aims at improving lifestyle and health outcomes by focusing on improving diet, increasing activity levels and reducing stress. In this study, the feasibility of the newly developed digital behavioral change program (SK-241) will be evaluated in a minimum of 30 individuals with a NAFLD diagnosis. The primary aim is to explore the acceptability of the SK-241 program by its users, in addition to exploring changes in clinical outcomes and medication adherence after a 12-week intervention with 6 months follow up.

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

DEVICE

A digital care solution for patients with NAFLD

A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.

Sponsors & Collaborators

  • Hjartamiðstöðin, Iceland

    collaborator UNKNOWN

  • Hjartavernd, Iceland

    collaborator UNKNOWN

  • Sidekick Health

    lead INDUSTRY

Principal Investigators

  • Sigríður Björnsdóttir, MD PhD · Hjartamiðstöðin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-20
Primary Completion
2023-04-24
Completion
2023-04-24

Countries

  • Iceland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05426382 on ClinicalTrials.gov